General Information of Drug (ID: DM1I8LU)

Drug Name
Coenzyme A Drug Info
Synonyms
coenzyme A; CoASH; CoA-SH; Zeel; 85-61-0; Depot-Zeel; CoA; HSCoA; Coenzym A; Coenzyme ASH; co-enzyme-A; UNII-SAA04E81UX; HS-CoA; SAA04E81UX; CHEBI:15346; 3'-phosphoadenosine-(5')diphospho(4')pantatheine; Coenzyme A hydrate; co-A; Co-A-SH; Reduced CoA; 3'-phosphoadenosine 5'-{3-[(3R)-3-hydroxy-2,2-dimethyl-4-oxo-4-({3-oxo-3-[(2-sulfanylethyl)amino]propyl}amino)butyl] dihydrogen diphosphate}
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
87642
ChEBI ID
CHEBI:15346
CAS Number
CAS 85-61-0
TTD Drug ID
DM1I8LU
VARIDT Drug ID
DR00302

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
Drug Status:
Discontinued Drug(s)
Approved Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Teglicar DMPCRUT Diabetic complication 5A2Y Discontinued in Phase 2 [6]
LXR-015-2 DMXYDJR Ischemia 8B10-8B11 Terminated [7]
Drug(s) Targeting HMG-CoA reductase (HMGCR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [8]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [9]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [10]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [11]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [12]
Fluvastatin DM4MDJY Arteriosclerosis BD40 Approved [9]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [13]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [9]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [14]
Teriflunomide DMQ2FKJ Hyperlipidaemia 5C80 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetoacetyl-Coenzyme A DM3HYU8 Discovery agent N.A. Investigative [2]
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [15]
Drug Name Drug ID Indication ICD 11 Highest Status REF
PTX-007011 DM89RT7 Bacterial infection 1A00-1C4Z Terminated [16]
2-Methyl-2,4-Pentanediol DMD45CU Discovery agent N.A. Investigative [2]
4'-Phosphopantetheine DMJ0A4Z Discovery agent N.A. Investigative [2]
Dephospho Coenzyme A DMGHM1L Discovery agent N.A. Investigative [17]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Adenosine monophosphate DMNIJT0 Malnutrition 5B50-5B71 Approved [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Pantothenate kinase (Bact coaA) TTSEOPJ COAA_ECOLI Inhibitor [2]
Carnitine acyltransferase (CRAT) TTC8M31 CACP_HUMAN Inhibitor [2]
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [2]
Phosphopantetheine adenylyltransferase (PPAT) TT4YO0Z COASY_HUMAN Inhibitor [2]
Staphylococcus DHNA-CoA synthase (Stap-coc menB) TT8HWCD MENB_STAAC Inhibitor [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Graves disease carrier protein (SLC25A16) DTNU9EW GDC_HUMAN Substrate [3]
Mitochondrial coenzyme A transporter SLC25A42 (SLC25A42) DTU4HKJ S2542_HUMAN Substrate [4]
Peroxisomal membrane protein PMP34 (SLC25A17) DTYR5U7 PM34_HUMAN Substrate [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3044).
2 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3 Biochemical characterization of a new mitochondrial transporter of dephosphocoenzyme A in Drosophila melanogaster. Biochim Biophys Acta Bioenerg. 2017 Feb;1858(2):137-146.
4 A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3',5'-diphosphate in human mitochondria. J Biol Chem. 2009 Jul 3;284(27):18152-9.
5 The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012 Apr 1;443(1):241-7.
6 Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes. 2011 February; 60(2): 644-651.
7 EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury. Brain Res. 2006 Nov 6;1118(1):168-75.
8 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
9 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
10 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
11 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
12 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
13 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
14 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
15 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
16 NME DIGEST. Drug News & Perspect 2002, 15(8):519, ISSN 0214-0934.
17 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.